GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

For many people suffering from asthma, the winter months and the colder air can trigger asthma symptoms and flare-ups, which ...

MUNICH, Germany I January 30, 2025 I Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced ...

A novel asthma burden score accurately assesses asthma severity and predicts remission, according to findings published in ...

Dr. Neha Reshamwala, owner of Frontier Allergy, Asthma & Immunology, with BioBehavioral Research of Austin (BBRA) stopped by ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...